Stem Cell Therapy for Frailty: What the Laromestrocel Trial Shows

Picture a 78-year-old woman who used to walk to the mailbox and back without thinking about it.

Now she stops halfway. Her legs feel heavy. She gets tired faster. A cold that used to last a week knocks her flat for a month. Her doctor uses a word she does not like: frail.

Frailty is not a disease in the usual sense. It is a state of low reserve. The body has less margin to absorb a fall, an infection, or a surgery. Researchers estimate that 12% to 24% of people 65 and older are frail, and the share climbs with age. There is no FDA-approved drug for it. The best-supported tools today are exercise, nutrition, and careful medical care.

So when a stem cell trial in frailty reports that people walked farther, it gets attention. It should. It also deserves a close read, because the details matter more than the headline. Let's go through them.

What Is Frailty, and Why Are Researchers Testing Stem Cells for It?

Doctors usually score frailty with tools like the Clinical Frailty Scale. A score of 5 means "mildly frail." A score of 6 means "moderately frail." People in that range can still live at home, but they need help with harder tasks and they slow down noticeably.

One idea behind the research is something scientists call "inflammaging." As we age, many people carry a low, constant level of inflammation. Markers like TNF-alpha run higher. Small blood vessels work less well. Researchers suspect this background inflammation feeds the loss of strength and stamina.

MSCs are of interest because, in lab and early human studies, they release signaling molecules that affect the immune system and blood vessels. The current scientific view is that infused MSCs do not stay in the body long. They are thought to act mainly through the signals they send, not by turning into new muscle. Whether that translates into real-world function in frail people is exactly what these trials are trying to answer.

What Did the Laromestrocel Phase 2b Trial Test?

Laromestrocel (also called Lomecel-B) is an investigational product made by Longeveron, a Miami biotech company. It is made from bone marrow MSCs taken from adult donors and grown in a lab. It is studied as a drug under FDA rules, which is why it has to go through phased clinical trials.

Here is how the Phase 2b study was built:

• Who: Adults aged 70 to 85 with a Clinical Frailty Scale score of 5 or 6, a 6-minute walk distance between 200 and 400 meters, and a raised TNF-alpha level. People with dementia, Parkinson's disease, recent cancer, or autoimmune disease were excluded.
• Where: Eight sites, mostly in South Florida, including the Miami VA. The National Institute on Aging partly funded it.
• Groups: 148 people got one IV infusion of placebo (30 people) or 25 million (37), 50 million (31), 100 million (34), or 200 million (16) cells. It was double-blind.
• Main measure: Change in 6-minute walk distance, with the registered primary time point at day 180.
• Follow-up: 12 months. Mean age was about 75. Average starting walk distance was about 305 to 317 meters.

The trial ran from 2017 to 2021. The company reported top-line results in August 2021. The full peer-reviewed paper appeared in Cell Stem Cell on February 25, 2026.

What Did the Results Show?

This is where you have to read slowly. There are two stories in the data, and both are true.

The encouraging part

• A dose-response signal. At day 180, statistical models testing whether higher doses produced bigger gains came back positive (the best-fitting model had p = 0.017). In plain words: more cells tended to go with more walking distance.
• A bigger gap at 9 months. At day 270, the 200-million-cell group walked 63.4 meters farther than placebo (95% CI 17.1 to 109.6 m; p = 0.0077). The 50-million group was 49.2 meters ahead (p = 0.012). The authors note that minimal meaningful changes in this test are usually put somewhere between about 18 and 32 meters, depending on the population.
• Fewer people rated frail. By month 9, the treated groups showed a numeric shift toward less severe Clinical Frailty Scale scores compared with placebo.
• A possible biomarker. Higher doses were linked with lower blood levels of soluble TIE2, a marker tied to blood vessel health. The authors suggest it might one day help predict who responds.

The part that tempers it

• The main time point did not hit. At day 180, after adjusting for testing four doses at once, no single dose beat placebo. The 200-million group was 41.3 meters ahead, but the result did not reach statistical significance (p = 0.0635).
• The 9-month result was exploratory. The day-270 comparison was pre-specified, but as an exploratory endpoint, not the primary one. Exploratory wins are hints, not proof.
• Doses did not line up neatly. At 9 months, the 25-million and 100-million groups were not significantly different from placebo, while the 50-million and 200-million groups were.
• Other function tests were flat. Gait speed and grip strength did not improve significantly. A key secondary endpoint, the PROMIS physical function questionnaire at day 180, did not differ from placebo. Most other exploratory measures (falls risk, mood, cognition, lung function) did not show significant differences at most time points.
• Small groups. The headline 200-million group had only 16 people. The authors list the small group sizes as a limitation.

How Does This Compare With Earlier Frailty Stem Cell Trials?

The Phase 2b did not come out of nowhere. Two smaller studies came first, both from the same University of Miami research group.

Notice something. In the 30-person trial, the 100-million dose looked best and the 200-million dose did not separate from placebo. In the 148-person trial, the 200-million dose looked best and the 100-million dose did not separate at 9 months. That kind of inconsistency is common in early research. It is one more reason the field needs a larger confirmatory trial before anyone draws firm conclusions.

Was It Safe?

Across the Phase 2b study, the rate of treatment-emergent serious adverse events was similar between groups, and investigators attributed no serious adverse events to the cells. An independent data safety monitoring board appointed by the National Institute on Aging raised no safety concerns.

Two people died during the study. One, in the 100-million group, died of a pulmonary embolism 296 days after infusion. The other, in the placebo group, died 167 days after infusion. Two infusions in the 25-million group were briefly paused and then completed.

Safety data from 148 people followed for a year is useful. It is not the same as the data from thousands of people that a full approval usually needs. Rare risks, and risks in sicker or older people, would only show up in larger studies. For a general overview, see our page on stem cell therapy side effects.

What Happens Next for Stem Cell Therapy in Frailty?

As of October 2026, Longeveron's own pipeline lists aging-related frailty at Phase 2. Here is what has happened since the paper came out:

• XPRIZE Healthspan. In August 2026, Longeveron was named one of 20 finalists in the XPRIZE Healthspan competition and received a $1 million milestone award, according to the University of Miami. The company plans a new randomized trial measuring walk distance, immune function, and cognitive function, with enrollment expected to start in summer 2027. Finalists submit data in 2029.
• A setback in another program. On September 16, 2026, Longeveron reported that its Phase 2b trial of laromestrocel in infants with a rare heart defect (hypoplastic left heart syndrome, 40 patients) did not meet its primary endpoint. The company said it is cutting costs and reviewing strategic options. That trial tested a different condition and a different delivery method, so it says nothing direct about frailty. But it may affect how fast the frailty program moves.

So the honest status is this: one mid-size trial with an encouraging but mixed signal, two small earlier trials, and a confirmatory study that has not started yet. That is a promising place for a field to be. It is not the finish line.

This pattern is not unique to frailty. The same thing happened in knee arthritis, where newer, larger trials gave a more sober picture than early studies. We covered that in what the 2026 knee osteoarthritis trials show. And it took years of trials before the FDA approved its first MSC product for one narrow use, which we explain in Ryoncil, the first FDA-approved MSC therapy.

Does This Research Apply to Other Stem Cell Products?

No, not directly. And this is the part most marketing skips.

Clinical trial results belong to the specific product that was tested. Laromestrocel is a bone marrow-derived MSC product, grown in a lab under a specific manufacturing process, given as a single IV infusion at doses up to 200 million cells. A different cell source, a different manufacturer, a different dose, or a different number of treatments is a different product. Its effects, good or bad, have to be studied on their own.

That is not a knock on any product. It is how evidence works. When you read "stem cells helped frail patients walk farther," the right question is: which cells, made by whom, at what dose, in what study?

Where The Stem Cell Club Fits

Plain answer: we do not offer laromestrocel. We are not part of Longeveron's trials, and we have no connection to the company.

We offer umbilical cord Wharton's Jelly MSC options sourced from an FDA-registered U.S. lab. That is a different cell source, made by a different lab, at different cell counts than the products in these frailty trials. Lab registration covers facility and manufacturing standards. It is not FDA approval of a therapy. Our offerings are not FDA-approved to diagnose, treat, cure, or prevent any disease, including frailty, and they are not a substitute for exercise, physical therapy, nutrition, or care from your own doctor.

If frailty is on your mind, for yourself or a parent, the first conversation should be with a primary care doctor or geriatrician. Ask about strength and balance programs, protein and vitamin D, medication review, and fall prevention. Those have the strongest evidence today. If you want to look into research studies, search ClinicalTrials.gov and bring what you find to that appointment. For how FDA approval, trials, and lab registration differ, see stem cell therapy and FDA approval.

Questions to Ask Before You Believe Any "Stem Cells for Aging" Claim

• Was there a placebo group? Older adults often improve for a while just from being in a study and getting more attention.
• Did the main endpoint succeed? Or is the claim built on a secondary or exploratory result?
• How many people got that exact dose? Sixteen people is a starting point, not a verdict.
• Which measures did not improve? Honest sources tell you what failed, too.
• Is it the same product? Results from one company's bone marrow cells do not transfer to another company's cord cells, or the other way around.

We keep a longer checklist here: questions to ask any stem cell clinic.

Frequently Asked Questions